NASDAQ
No price data available for this timeframe.
Total Transactions
15
5 buys /10 sells
Shares Acquired
6,356
Transactions: 5•Avg: 1,271.2
Shares Disposed
12,712
Transactions: 10•Avg: 1,271.2
Net Activity
-6,356
Net Selling•Ratio: 50%
Q4 2025(Current) | 6,356 | 12,712 | -6,356 | 50.00% |
Q3 2025 | 84,589 | 97,942 | -13,353 | 61.11% |
Q2 2025 | 247,841 | 135,579 | +112,262 | 137.50% |
Q1 2025 | 612,853 | 119,427 | +493,426 | 100.00% |
Q4 2024 | 10,200 | 62,924 | -52,724 | 16.67% |
This table shows insider trading activity by quarter. A ratio > 100% indicates insiders acquired more shares than they disposed of during the period, which is generally considered a bullish signal.
• Most recent data for Q4 2025
Acquired vs Disposed Shares
Net Distribution: 6,356 shares•Acquired/Disposed Ratio: 50%
Net Activity | |||||
|---|---|---|---|---|---|
FJA FOUSE JACQUALYN A | Director | 5 | 36,637 | 2,120 | +34,517 |
GB Goff Brian | Director, officer: chief executive officer | 9 | 60,968 | 90,753 | -29,785 |
BJT Backstrom Jay T. | Director | 3 | 27,734 | 0 | +27,734 |
GS Gheuens Sarah | Officer: chief medical officer | 19 | 32,244 | 57,114 | -24,870 |
CJD CAPELLO JEFFREY D | Director | 6 | 22,726 | 4,097 | +18,629 |
This table shows the trading activity of the most active company insiders. Positive net activity (buying more than selling) is often considered a bullish signal.
2025-11-12 | Director | Sale | 200 | $18.09 | $3,618 | 26,907 | |
2025-11-12 | Director | Purchase | 200 | $18.09 | $3,618 | 17,803 | |
2025-11-12 | Director | Sale | 200 | $43.84 | $8,768 | 17,603 | |
2025-11-11 | Officer: chief medical officer | Purchase | 2,454 | $25.01 | $61,374.54 | 64,181 | |
2025-11-11 | Officer: chief medical officer | Sale | 2,454 | $43.78 | $107,436.12 | 61,727 |
This table displays recent Form 4 filings showing transactions by company insiders. SEC rules require insiders to report their transactions within two business days.
SD Scadden David | Director | Nov 14, 2025 | |
SD Scadden David | Director | Nov 14, 2025 | |
SD Scadden David | Director | Nov 14, 2025 | |
GS Gheuens Sarah | Officer: chief medical officer | Nov 13, 2025 | |
GS Gheuens Sarah | Officer: chief medical officer | Nov 13, 2025 |
Net change in shares shown on right